为什么倍氯米松-氢氟烷烃的有效剂量仅为倍氯米松-氯氟烷烃的二分之一被引量：1

导出

摘要根据“蒙特利尔议定书”，气雾剂中的驱动剂氯氟烷烃（又称为氟利昂，Chlorofluorocarbon，CFC）将全面禁用，最终被氢氟烷烃（Hydrofluoroalkane，HFA）替代。CFC具有较强的臭氧层破坏作用[1]，淘汰是必须的，我国确定CFC-MDI的最后淘汰日期是2017年12月31日[2]。

作者叶晓芬蔡映云吕迁洲

机构地区复旦大学附属中山医院药齐

出处《中华结核和呼吸杂志》 CAS CSCD 北大核心 2015年第6期470-471,共2页 Chinese Journal of Tuberculosis and Respiratory Diseases

关键词氢氟烷烃倍氯米松有效剂量臭氧层破坏蒙特利尔氟利昂气雾剂 CFC

分类号 R95 [医药卫生—药学]

引文网络
相关文献

参考文献13

1薛峰,金方.吸入制剂在哮喘和慢性阻塞性肺疾病治疗中的作用及地位[J].世界临床药物,2012,33(4):245-249. 被引量：20
2周新.定量吸入气雾剂临床应用现状与研究进展[J].中华结核和呼吸杂志,2013,36(3):213-215. 被引量：10
3Global Initiative for Asthma (GINA).Global strategy for asthma management and prevention (updated 2010)[J].http://www.ginasthma.org/local/uploads/files/GINA_Report_2010_1.pdf.
4Global Initiative for Asthma (GINA).Global strategy for asthma management and prevention (updated 2012)[J].http://www.ginasthma.org/local/uploads/files/GINA _ Report _ March13 _ 1.pdf.
5Global Initiative for Asthma (GINA).Global strategy for asthma management and prevention (revised 2014)[J].http://www.ginasthma.org/local/uploads/files/GINA_ Report_2014 _ Aug12.pdf.
6Leach CL,Davidson PJ,Boudreau RJ.Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone[J].Eur Respir J,1998,12 (6):1346-1353.
7Goldin JG,Tashkin DP,Kleerup EC,et al.Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways:Assessment with functional helical thinsection computed tomography[J].J Allergy Clin Immunol,1999,104(6):S258-267.
8Seale JP,Harrison LI.Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics[J].Respir Med,1998,92 (Suppl A):9-15.
9Harrison LI,Soria I,Cline AC,et al.Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics[J].J Pharm Pharmacol,1999,51 (11):1235-1240.
10Leach C.Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans[J].J Allergy Clin Immunol,1999,104(6):S250-252.

二级参考文献25

1王长征.哮喘发病的“卫生学说”及有关的争议[J].中国呼吸与危重监护杂志,2005,4(5):397-398. 被引量：11
2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量：8230
3钮善福.吸入疗法.朱元珏,陈文彬主编.呼吸病学.第1版[M].北京:人民卫生出版社,2003: 632-640.
4Dhand R. Future directions in aerosol therapy. Respir Care Clin North Am, 2001, 7:319-335.
5Gabrio B J, Stein SW, velsaquez DJ. A new method to evaluate plume characteristics of hydrofluorocalkane and chorofluorocarbon metered dose inhalers. Int J Pharm, 1999, 186:3-12.
6Vanden Burgt JA, Basse WW, Martin R J, et al. Efficacy and satety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extraline inhalation aerosol ), in asthma. J Allergy Clin Immunol, 2000, 106 : 1209-1226.
7Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. ERS/ISAM task force report. Eur Rdspir J, 2011, 37: 1308-1331.
8Lewis DA, Ganderton D, Meakin BJ, et al. Modulite a simple solution to a difficult problem. Respiration, 2005, 72:3-5.
9Dhilton S, Keating GM. Beclometasone dipropionate/formoterol: in an HFA-propelled pressured metered-dose inhaler. Durgs, 2006, 66 : 1474-1483.
10Menzies D, Nair A, Hopkinson P, et al. Differential anti- inflammatory effects of large and small particle size inhaled corticosteroids in asthma. Allergy, 2007, 62:661-667.